FindTrial
Sign In

To study the ability of Olanzapine to control Cisplatin-induced emesis

Olanzapine for control of Cisplatin-induced emesis: A prospective randomised study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/038303
Enrollment
150
Registered
2021-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Granisetron Dexamethasone Olanzapine: Inj. Granisetron IV 1mg as premedication on D1 (Day 1) Inj. Dexamethasone IV 12mg as premedication on D1 T. Olanzapine PO 5mg 0-0-1 on D1 and D2 Co

Sponsors

Dr P Rama
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients receiving Cisplatin will be recruited.

Exclusion criteria

Exclusion criteria: 1. Patients who deviate from the already designed protocol 2. Pregnant and lactating women 3. Psychiatric patients 4. Patients with arrythmia 5. Patients with renal impairment (Creatinine clearance: <15ml/min/1.73m 2 ) 6. Patients treated with Amitriptyline 7. Patients experiencing nausea/ vomiting due to mechanical obstruction

Design outcomes

Primary

MeasureTime frame
To determine the effectiveness of Olanzapine in control of nausea and vomiting.Timepoint: The questionnaire will be answered and Nausea and Vomiting will be graded as per CTCAE prior to the successive chemotherapy cycle. Therefore, on a weekly basis.—

Secondary

MeasureTime frame
To assess the quality of life in patients experiencing nausea and vomiting.Timepoint: FLIE Questionnaire will be answered prior to the succesive cycle. Therefore, on a weekly basis.—

Countries

India

Contacts

Public ContactSanta Treasa Cyriac

PSG College of Pharmacy

treesacyr@gmail.com9789216716

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026